April 25, 2019. Monoclonal antibodies to treat rabies exposure could provide a beneficial treatment option, but they need clear and unambiguous evidence of their safety and efficacy.
Read More »On Medical Treatments & Products
Statement on Behalf of Members of the Patient, Consumer, and Public Health Coalition at the FDA Advisory Committee on Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and Informed Consent
March 26, 2019. NCHR testified at the FDA advisory committee meeting on Breast Implants on improving informed consent procedures for informing patients on risks of BIA-ALCL
Read More »NCHR Testimony to FDA on NeuroAD Therapy System in Alzheimer’s Patients
March 21, 2019. NCHR testifies at an FDA Neurological Devices Advisory Committee regarding NeuroAD, a proposed treatment for Alzheimer’s dementia.
Read More »NCHR Comments on USPSTF’s on Pancreatic Cancer Screening
March 4, 2019. We support the USPSTF’s draft recommendation against screening for pancreatic cancer in asymptomatic adults because screening asymptomatic adults does not improve patient outcomes and poses its own risks.
Read More »NCHR Testimony to FDA on Selinexor for Relapsed Refractory Multiple Myeloma
February 26, 2019. Selinexor has serious risks, and we don’t know if it works. Tell FDA to wait until the randomized trial is analyzed to make a decision.
Read More »